Aldeyra The

ALDX.US
Healthcare · Biotechnology
1.58
-0.01 (-0.32%)
USD · NASDAQ

Company Information

Company Name
Aldeyra The
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
ISIN: US01438T1060
CIK: 0001341235
CUSIP: 01438T106
Currency: USD
Full Time Employees: 7
Phone: 781 761 4904
Fiscal Year End: December
IPO Date: May 02, 2014
Description:

Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP) modulator, which is in Phase III clinical trial for the treatment of dry eye disease and allergic conjunctivitis; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment of primary vitreoretinal lymphoma and retinitis pigmentosa. The company also develops ADX-629, an orally administered RASP modulator that is in Phase 2 clinical trials for the treatment of COVID-19, atopic asthma, psoriasis, and alcohol intoxication. In addition, it develops preclinical RASP platforms, including ADX 248, ADX 246, and other novel RASP modulators for the treatment of various diseases associated with RASP. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.

Address:

131 Hartwell Avenue, Lexington, MA, United States, 02421

People

Directors & Officers

Name Title Year Born
Dr. Todd C. Brady M.D., Ph.D. CEO, President & Director 1972
Mr. Michael Alfieri Head of Finance and Principal Financial & Accounting Officer 1965
David Burke Head of Investor Relations NA
Laura Nichols Operations Manager NA
Dr. Adam Lazorchak Director of Translational Sciences & Non-Clinical Development NA

Insider Trading

Date Insider Name Title Transaction Type Shares Price Value
Mar 19, 2026 Richard Douglas N/A Purchase 70.00K $1.40 $98.00K
Mar 18, 2026 Michael Alfieri N/A Purchase 5.00K $1.42 $7.10K
Aug 11, 2025 Stephen Machatha N/A Sale 22.07K $5.15 $113.68K

Shareholders

Institutional Holders

Holder Name Shares Date Reported % Out Value % Change
Knoll Capital Management LP 5.48M Mar 31, 2026 9.08% $5.14 0.00%
BlackRock Inc 3.76M Mar 31, 2026 6.24% $0.00 -2.24%
Vanguard Group Inc 3.70M Dec 31, 2025 6.13% $0.00 2.97%
AQR Capital Management LLC 2.83M Mar 31, 2026 4.69% $0.00 130.65%
Vanguard Capital Management, LLC 2.36M Mar 31, 2026 3.92% $0.00 0.00%
Kingdon Capital Management LLC 2.15M Mar 31, 2026 3.57% $0.40 16.34%
683 Capital Management LLC 1.50M Mar 31, 2026 2.49% $0.13 -1.96%
D. E. Shaw & Co LP 1.40M Mar 31, 2026 2.33% $0.00 -12.32%
Geode Capital Management, LLC 1.25M Mar 31, 2026 2.08% $0.00 6.93%
State Street Corp 1.12M Mar 31, 2026 1.86% $0.00 2.38%
Millennium Management LLC 995.24K Mar 31, 2026 1.65% $0.00 2,158.89%
Ardsley Advisory Partners 975.00K Jun 30, 2026 1.62% $0.22 2.63%
Jane Street Group LLC 968.89K Mar 31, 2026 1.61% $0.00 218.87%
Renaissance Technologies Corp 863.19K Mar 31, 2026 1.43% $0.00 146.62%
Acadian Asset Management LLC 858.29K Mar 31, 2026 1.42% $0.00 652.05%
Vanguard Portfolio Management, LLC 807.78K Mar 31, 2026 1.34% $0.00 0.00%
Jacobs Levy Equity Management, Inc. 796.82K Mar 31, 2026 1.32% $0.01 -17.75%
Propel Bio Management LLC 730.61K Mar 31, 2026 1.21% $0.78 0.00%
Dimensional Fund Advisors, Inc. 624.17K Mar 31, 2026 1.03% $0.00 1.95%
The Goldman Sachs Group Inc 543.15K Mar 31, 2026 0.90% $0.00 77.67%

Fund Holdings

Rank Holder Name Shares Held % of Shares Change Date Reported
1 Vanguard Total Stock Mkt Idx Inv 1.78M 2.96% ▲ 0.00% Jun 30, 2026
2 Fidelity Small Cap Index 540.29K 0.90% ▼ 0.14% Apr 30, 2026
3 Vanguard Institutional Extnd Mkt Idx Tr 521.52K 0.86% ▲ 0.00% Jun 30, 2026
4 Vanguard Explorer Inv 331.51K 0.55% ▲ 0.00% Mar 31, 2026
5 Fidelity Extended Market Index 262.16K 0.43% ▼ 11.71% May 31, 2026
6 iShares Micro-Cap ETF 187.53K 0.31% ▲ 0.00% Jun 30, 2026
7 DFA US Small Cap I 165.09K 0.27% ▲ 0.00% May 31, 2026
8 Vanguard Health Care ETF 155.21K 0.26% ▲ 0.39% Jun 30, 2026
9 DFA US Micro Cap I 140.33K 0.23% ▲ 0.00% May 31, 2026
10 Extended Equity Market Fund B 114.70K 0.19% ▼ 0.05% Dec 31, 2025

Financial Highlights

Market Cap: $95.61M
EBITDA: $-28.13M
PEG Ratio: $0.00
Book Value: $0.70
Earnings/Share: $-0.47
Profit Margin: 0.00%
Operating Margin: 0.00%
ROA (TTM): -22.22%
ROE (TTM): -51.76%
Revenue (TTM): $0.00
Revenue/Share (TTM): $0.00
Earnings Growth (YOY): 0.00%
Revenue Growth (YOY): 0.00%

Valuation Metrics

Enterprise Value: $42.20M
Trailing P/E: 0.00
Forward P/E: 0.00

Shares Statistics

Shares Outstanding: 60.32M
Shares Float: 52.68M
% Insiders: 359.70%
% Institutions: 6,270.00%
Short % Float: 6.16%

Stock Price History

1 Year Price History

2 Years Price History

5 Years Price History

10 Years Price History

Financial Charts

Revenue & Net Income (Yearly)

Revenue & Net Income (Quarterly)

Operating Expenses (Yearly)

Operating Expenses (Quarterly)

Balance Sheet (Quarterly)

Assets Breakdown (Yearly)

Assets Breakdown (Quarterly)

Liabilities Breakdown (Yearly)

Liabilities Breakdown (Quarterly)

Income Statement Waterfall

Open full waterfall
Line Item
Step Type
Value
Revenue
adjust
$0.00
Cost of Goods Sold
adjust
$-251.99K
Gross Profit
subtotal
$-251.99K
SG&A
adjust
$-9.60M
R&D
adjust
$-25.66M
Operating Income
subtotal
$-35.27M
Other / Non-Operating Items
adjust
$1.42M
Net Income
subtotal
$-33.85M

Earnings Per Share (EPS) History

Financial Ratios

📦 Raw API Data (JSON Explorer)

Watchlist

0

No stocks in watchlist

Assistant

×
Hello! I'm your AI assistant. I have access to the financial data on this page. Ask me anything about ALDX.US!